Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 24Breast Neoplasms 20Lymphoma 9Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia, Myeloid, Acute 6Precancerous Conditions 5Multiple Myeloma 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Congenital Abnormalities 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Colorectal Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma Of Esophagus 4Wilms Tumor 3Rectal Neoplasms 3Prostatic Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neuroblastoma 3

Interventions

Dexamethasone 50Melphalan 29Cyclophosphamide 25Bortezomib 24Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8fludarabine phosphate 7ixazomib 6dexamethasone 21-phosphate 6Whole-Body Irradiation 6Mycophenolic Acid 6venetoclax 5birtamimab 5auricularum 5Thalidomide 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Busulfan 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Biopsy 4sargramostim 3miridesap 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡